Agenus reported $35.54M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.3B 19M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Celldex Therapeutics USD 4.9M 3M Jun/2026
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Incyte USD 38.27M 1.16M Jun/2026
Intrexon USD 0 13.82M Jun/2024
J&J USD 49.04B 5.95B Jun/2026
Jiangsu Hengrui CNY 421.65M 353.67M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 35.09M 1.42M Jun/2026
Merck EUR 12.3B 264M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Northwest Biotherapeutics USD 32.94M 6.93M Sep/2023
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 62.67B 523M Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 40.11M 774K Jun/2026